Top Page
Terumo
(OTC:4543)
Terumo (4543) vs. iShares MSCI Japan ETF (EWJ)
Terumo Business Overview & Revenue Model
Terumo Earnings Call Summary
Terumo Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04T | 1.04T | 921.86B | 820.21B | 703.30B | 613.84B |
| Gross Profit | 568.57B | 560.67B | 454.17B | 417.37B | 369.34B | 326.62B |
| EBITDA | 255.56B | 246.74B | 197.69B | 188.44B | 175.55B | 151.38B |
| Net Income | 124.93B | 116.98B | 106.37B | 89.33B | 88.81B | 77.27B |
Balance Sheet | ||||||
| Total Assets | 1.80T | 1.83T | 1.83T | 1.60T | 1.47T | 1.35T |
| Cash, Cash Equivalents and Short-Term Investments | 204.29B | 222.15B | 206.33B | 187.38B | 205.31B | 200.83B |
| Total Debt | 169.85B | 213.96B | 268.55B | 266.67B | 259.01B | 293.08B |
| Total Liabilities | 430.36B | 459.85B | 504.31B | 491.16B | 461.37B | 494.53B |
| Stockholders Equity | 1.37T | 1.37T | 1.33T | 1.11T | 1.01T | 856.66B |
Cash Flow | ||||||
| Free Cash Flow | 137.39B | 142.19B | 85.60B | 64.84B | 87.95B | 59.17B |
| Operating Cash Flow | 207.74B | 210.80B | 146.33B | 117.54B | 141.47B | 121.48B |
| Investing Cash Flow | -83.66B | -82.48B | -81.47B | -59.12B | -78.45B | -85.32B |
| Financing Cash Flow | -101.37B | -108.77B | -62.08B | -86.56B | -70.88B | -7.44B |
Terumo Technical Analysis
Terumo Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.87T | 38.46 | 21.19% | 0.89% | 9.89% | 10.30% | |
| ― | $2.07T | 18.64 | 14.88% | 1.05% | 0.59% | 557.87% | |
| ― | ¥3.67T | 30.27 | 9.17% | 1.13% | 7.58% | 6.74% | |
| ― | $1.14T | 23.83 | 10.48% | 1.71% | 5.09% | -9.10% | |
| ― | $628.13B | 49.29 | 8.67% | 1.02% | 11.60% | -19.38% | |
| ― | ¥244.24B | 43.51 | 2.49% | 2.00% | 8.83% | -40.24% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Terumo Corporate Events
Terumo Corporation announced an amendment to its Shareholder Benefit Program, effective from March 31, 2026. The changes aim to increase shareholder engagement by offering electronic coupons and exclusive benefits to long-term shareholders, thereby enhancing the investment appeal and promoting a deeper understanding of its business activities.
The most recent analyst rating on (JP:4543) stock is a Buy with a Yen2915.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.
Terumo Corporation has announced its acquisition of OrganOx Limited for approximately USD 1.5 billion, marking its strategic entry into the organ transplantation sector. This move is expected to enhance Terumo’s business portfolio and address significant unmet medical needs by improving organ preservation and utilization rates, ultimately benefiting transplant patients and healthcare providers globally.
The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3165.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.
Terumo Corporation is a leading Japanese medical device company listed on the Tokyo Stock Exchange, specializing in cardiac and vascular solutions, medical care solutions, and blood and cell technologies.
During the recent earnings call, Terumo conveyed a mixed sentiment, marked by robust revenue and profit growth, particularly in the Americas and cardiovascular segments. However, the company also expressed concerns over tariff impacts, temporary revenue declines in certain segments, and a decrease in free cash flow.
Terumo Corporation reported a modest increase in revenue for the three months ended June 30, 2025, with a 0.7% rise compared to the previous year. However, the company saw significant growth in operating profit and profit before tax, indicating improved operational efficiency. The financial results highlight Terumo’s strong market positioning and its ability to enhance profitability despite a challenging market environment. The company also announced an increase in its annual dividend guidance, reflecting confidence in its financial stability and commitment to shareholder returns.
The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.
Terumo Corporation has finalized the details regarding the issuance of stock options, specifically Share Warrants No.13, as resolved in their July 17, 2025 Board of Directors meeting. The allocation involves 5,233 warrants distributed among group executive officers, executive officers, and fellows, with a subscription price set at 18,960 yen per warrant. This move is likely aimed at incentivizing leadership and aligning their interests with the company’s long-term goals.
The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.
Terumo Corporation has completed the disposal of 101,606 treasury shares as part of its Restricted Stock remuneration plan. This move, involving directors, executive officers, Terumo Fellows, and employees, signifies a strategic step in aligning the interests of its key stakeholders with the company’s performance, potentially enhancing its market positioning and operational focus.
The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.